SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193125-16-785218
Filing Date
2016-12-05
Accepted
2016-12-05 16:51:02
Documents
2
Group Members
ANSBERT GADICKEMPM ONCOLOGY IMPACT MANAGEMENT GP LLCMPM ONCOLOGY IMPACT MANAGEMENT LPONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G d292280dsc13g.htm SC 13G 92989
2 EX-99.A d292280dex99a.htm EX-99.A 10780
  Complete submission text file 0001193125-16-785218.txt   105403
Mailing Address 86 SOUTH STREET HOPKINTON MA 01748
Business Address 86 SOUTH STREET HOPKINTON MA 01748 508-473-5993 X119
Spring Bank Pharmaceuticals, Inc. (Subject) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-89626 | Film No.: 162034311
SIC: 2834 Pharmaceutical Preparations

Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Filed by) CIK: 0001691428 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G